Aseptic, isolator‑based fill‑finish spans multiple formats and batch sizes, supported by onsite analytics that cut hand‑offs and streamline testing. Learn how this setup boosts efficiency.
A U.S.-based sterile injectable CDMO delivering scalable small and large molecule manufacturing, supported by advanced aseptic technologies and integrated quality systems.
A framework for evaluating fill/finish CDMO RFPs beyond price and capacity, helping procurement teams uncover hidden costs, assess risk, and select partners built for scale.
End‑to‑end pharmaceutical contract manufacturing supporting development, scale‑up, and commercial production across biologics, small molecules, and advanced modalities.
Explore how integrated synthetic biology capabilities, advanced enzyme engineering, and global infrastructure can help streamline and accelerate biologic innovation.
Find comprehensive solutions with new sterile fill/finish investments supporting complex molecules through tech transfer, commercialization expertise, and integrated cGMP manufacturing.
Partner with a U.S.-based, trusted CDMO large enough to support every stage of your program, yet agile enough to deliver the dedicated care your project deserves.
Here, we walk you through our groundbreaking, enzymatic DNA manufacturing process that enables the production of linear DNA templates for IVT mRNA synthesis — without the use of cells.
Uncover how comprehensive drug product fill and finish services streamline the journey from formulation development to commercialization, ensuring quality and efficiency.
Check out our expert-led webinar on terminal sterilization vs. aseptic manufacturing, covering methods, regulatory expectations, and benefits for product safety, efficiency, and compliance.
